TaiGen Biopharmaceuticals Holdings Limited (TPEX: 4157)
14.50
+0.55 (3.94%)
Sep 10, 2024, 1:30 PM CST
TaiGen Biopharmaceuticals Holdings Company Description
TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide.
The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections.
It is also developing Taigexyn for treating community-acquired pneumonia and diabetic foot infection, as well as other bacterial infections; Burixafor, a stem cell mobilizer for stem cell transplantation and chemosenzitization; TG-1000, an influenza antiviral drug for treating influenza A, B, and avian influenza H7N9; and Furaprevir, a hepatitis C virus protease inhibitor for the treatment of chronic hepatitis C.
The company was founded in 2001 and is based in Taipei City, Taiwan.
TaiGen Biopharmaceuticals Holdings Limited
Country | Cayman Islands |
Founded | 2001 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Kuo-Lung Huang |
Contact Details
Address: No. 138, Xinming Road Taipei, 11470 Taiwan | |
Phone | 886 2 8177 7020 |
Website | taigenbiotech.com.tw |
Stock Details
Ticker Symbol | 4157 |
Exchange | Taipei Exchange |
Fiscal Year | January - December |
Reporting Currency | TWD |
ISIN Number | KYG866171005 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Kuo-Lung Huang | Chairman of the Board, Chief Executive Officer, President and Chief Commercial Officer in Asia |
Dr. Ming-Chu Hsu Ph.D. | Founder |
Richard Lu | Vice President of Finance |
Mark Kao | Head of the Accounting Department |
Dr. Peter W. Tsao M.B.A., Ph.D. | Vice President Corporate Development |